Our history
Creating value sustainably. For more than 150 years.
Our company’s story is one of change and of impact. Rentschler has always been about active pharmaceutical ingredients, highly effective medicines and improving the quality of life. As therapeutics have become more complex, so has their production. To this end, we are constantly expanding our expertise and our network, sustainably growing the relevance of Rentschler Biopharma on the international market.
More than 150 years of Rentschler
Entrepreneurial courage gives wings to innovation, regions, people, and entire generations: In 1872, strategically located on the Swabian Railway, the “7-Swabians Pharmacy” was established in Laupheim. This is our foundation from which we produce biopharmaceuticals for serious or rare diseases as a leading global contract development and manufacturing organization (CDMO). With subsidiaries in Milford (Boston, MA, USA) and Stevenage (UK), we have considerably expanded our presence and expertise, including in the field of cell and gene therapy.
Milestones
1872
Our roots go back to the G. Müller Pharmacy in Laupheim
1927
Foundation as a pharmaceutical manufacturer
1974
Installation of the biotechnology divison
1979
Start working with recombinant cell lines
1983
World's first market approval for a natural Interferon-ß (Fiblaferon)
1989
Approval of a recombinant Interferon-y (Polyferon) and a topical Interferon-ß-gel
1997
Entering the business of a contract development and manufacturing of biopharmaceuticals
2006
Foundation of Rentschler Biopharma Inc.
2008
Extension of manufacturing facilities (1 x 3,000 L stainless steel, 2 x 1,000 L single-use bioreactors)
2013
Implementing of own Combined Heat and Power plant
2014
Launch of proprietary cell line development platform TurboCellTM
2015
Manufacturing starts in the first 2,000 L single-use bioreactor
2016
Expansion of manufacturing capacity
2x 3,000 L twin facility, second 2,000 L single-use bioreactor
2017
Alliance between Rentschler Biopharma and Leukocare
Rentschler Biopharma will acquire a 10 % stake in Leukocare
2019
Acquisition of site in Milford, MA, USA
2020
Strategic collaboration with Vetter
2020
Entry into mRNA Technology
2021
New Modalities and site in Stevenage, UK
2021
Capacity Expansion with 2,000-liter bioreactor
2021
Groundbreaking for our new manufacturing line at our Milford site, MA, USA
2022
150 years of Rentschler
Get in Touch with our Communications Team
Dr. Latika Bhonsle-Deeng
Global Head of Communications and Spokesperson